Prestige Consumer Healthcare (PBH) 10-Q 6 Feb 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Dec. 31, 2019	Jan. 31, 2020
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-32433
Entity Registrant Name	PRESTIGE CONSUMER HEALTHCARE INC.
Entity Central Index Key	0001295947
Current Fiscal Year End Date	--03-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-1297589
Entity Address, Address Line One	660 White Plains Road
Entity Address, City or Town	Tarrytown
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10591
City Area Code	914
Local Phone Number	524-6800
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	PBH
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		50,265,837

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenues
Total revenues	$ 241,552	$ 241,414	$ 711,775	$ 734,751
Cost of Sales
Cost of sales excluding depreciation	102,900	100,997	300,318	313,713
Cost of sales depreciation	1,157	1,182	3,144	3,708
Cost of sales	104,057	102,179	303,462	317,421
Gross profit	137,495	139,235	408,313	417,330
Operating Expenses
Advertising and promotion	33,559	34,504	107,027	108,657
General and administrative	21,308	20,485	65,528	68,460
Depreciation and amortization	6,224	6,705	18,520	20,545
Gain on divestiture	0	0	0	(1,284)
Total operating expenses	61,091	61,694	191,075	196,378
Operating income	76,404	77,541	217,238	220,952
Other (income) expense
Interest income	(245)	(39)	(320)	(172)
Interest expense	24,520	26,366	74,092	79,509
Other (income) expense, net	(580)	218	695	640
Loss on extinguishment of debt	2,155	0	2,155	0
Total other expense	25,850	26,545	76,622	79,977
Income before income taxes	50,554	50,996	140,616	140,975
Provision for income taxes	12,496	12,829	35,381	37,501
Net income	$ 38,058	$ 38,167	$ 105,235	$ 103,474
Earnings per share:
Basic (in USD per share)	$ 0.76	$ 0.74	$ 2.07	$ 1.99
Diluted (in USD per share)	$ 0.75	$ 0.73	$ 2.05	$ 1.97
Weighted average shares outstanding:
Basic (in shares)	50,378	51,881	50,840	52,119
Diluted (in shares)	50,831	52,202	51,226	52,431
Comprehensive income, net of tax:
Currency translation adjustments	$ 3,497	$ (2,020)	$ (311)	$ (7,139)
Total other comprehensive income (loss)	3,497	(2,020)	(311)	(7,139)
Comprehensive income	41,555	36,147	104,924	96,335
Net sales
Revenues
Total revenues	241,545	241,411	711,729	734,719
Other revenues
Revenues
Total revenues	$ 7	$ 3	$ 46	$ 32

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Current assets
Cash and cash equivalents	$ 28,591	$ 27,530
Accounts receivable, net of allowance of $21,475 and $12,965, respectively	144,502	148,787
Inventories	121,363	119,880
Prepaid expenses and other current assets	5,913	4,741
Total current assets	300,369	300,938
Property, plant and equipment, net	53,233	51,176
Operating lease right-of-use assets	31,342	0
Finance lease right-of-use assets, net	5,895
Goodwill	577,635	578,583
Intangible assets, net	2,491,539	2,507,210
Other long-term assets	4,189	3,129
Total Assets	3,464,202	3,441,036
Current liabilities
Accounts payable	50,408	56,560
Accrued interest payable	14,482	9,756
Operating lease liabilities, current portion	6,377	0
Finance lease liabilities, current portion	1,159
Other accrued liabilities	76,610	60,663
Total current liabilities	149,036	126,979
Long-term debt, net	1,701,313	1,798,598
Deferred income tax liabilities	407,776	399,575
Long-term operating lease liabilities, net of current portion	26,200	0
Long-term finance lease liabilities, net of current portion	4,725
Other long-term liabilities	18,658	20,053
Total Liabilities	2,307,708	2,345,205
Commitments and Contingencies — Note 16
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock	537	536
Additional paid-in capital	485,838	479,150
Treasury stock, at cost - 3,525 shares at December 31, 2019 and 1,871 shares at March 31, 2019	(110,878)	(59,928)
Accumulated other comprehensive loss, net of tax	(26,058)	(25,747)
Retained earnings	807,055	701,820
Total Stockholders' Equity	1,156,494	1,095,831
Total Liabilities and Stockholders' Equity	$ 3,464,202	$ 3,441,036

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive Loss	Retained Earnings
Common stock, beginning balance (in shares) at Mar. 31, 2018		53,396,000
Equity, beginning balance at Mar. 31, 2018	$ 1,178,610	$ 534	$ 468,783	$ (7,669)	$ (19,315)	$ 736,277
Treasury stock, beginning balance (in shares) at Mar. 31, 2018				353,000
Stock-based compensation	$ 6,160		6,160
Exercise of stock options (in shares)	97,700	98,000
Exercise of stock options	$ 2,931		2,931
Issuance of shares related to restricted stock (in shares)		176,000
Issuance of shares related to restricted stock	$ 0	$ 2	(2)
Treasury share repurchases (in shares)	1,449,750			1,518,000
Treasury share repurchases	$ (52,259)			$ (52,259)
Net income	103,474					103,474
Comprehensive income (loss)	(7,139)				(7,139)
Common stock, ending balance (in shares) at Dec. 31, 2018		53,670,000
Equity, ending balance at Dec. 31, 2018	1,233,120	$ 536	477,872	$ (59,928)	(26,454)	841,094
Treasury stock, ending balance (in shares) at Dec. 31, 2018				1,871,000
Common stock, beginning balance (in shares) at Sep. 30, 2018		53,609,000
Equity, beginning balance at Sep. 30, 2018	1,193,238	$ 536	474,137	$ (59,928)	(24,434)	802,927
Treasury stock, beginning balance (in shares) at Sep. 30, 2018				1,871,000
Stock-based compensation	1,832		1,832
Exercise of stock options (in shares)		61,000
Exercise of stock options	1,903		1,903
Net income	38,167					38,167
Comprehensive income (loss)	(2,020)				(2,020)
Common stock, ending balance (in shares) at Dec. 31, 2018		53,670,000
Equity, ending balance at Dec. 31, 2018	1,233,120	$ 536	477,872	$ (59,928)	(26,454)	841,094
Treasury stock, ending balance (in shares) at Dec. 31, 2018				1,871,000
Common stock, beginning balance (in shares) at Mar. 31, 2019		53,670,000
Equity, beginning balance at Mar. 31, 2019	$ 1,095,831	$ 536	479,150	$ (59,928)	(25,747)	701,820
Treasury stock, beginning balance (in shares) at Mar. 31, 2019	1,871,000			1,871,000
Stock-based compensation	$ 5,682		5,682
Exercise of stock options (in shares)	36,000	36,000
Exercise of stock options	$ 1,007		1,007
Issuance of shares related to restricted stock (in shares)		73,000
Issuance of shares related to restricted stock	$ 0	$ 1	(1)
Treasury share repurchases (in shares)	1,622,544			1,654,000
Treasury share repurchases	$ (50,950)			$ (50,950)
Net income	105,235					105,235
Comprehensive income (loss)	(311)				(311)
Common stock, ending balance (in shares) at Dec. 31, 2019		53,779,000
Equity, ending balance at Dec. 31, 2019	$ 1,156,494	$ 537	485,838	$ (110,878)	(26,058)	807,055
Treasury stock, ending balance (in shares) at Dec. 31, 2019	3,525,000			3,525,000
Common stock, beginning balance (in shares) at Sep. 30, 2019		53,755,000
Equity, beginning balance at Sep. 30, 2019	$ 1,112,790	$ 537	483,595	$ (110,784)	(29,555)	768,997
Treasury stock, beginning balance (in shares) at Sep. 30, 2019				3,523,000
Stock-based compensation	1,780		1,780
Exercise of stock options (in shares)		18,000
Exercise of stock options	463		463
Issuance of shares related to restricted stock (in shares)		6,000
Issuance of shares related to restricted stock	0
Treasury share repurchases (in shares)				2,000
Treasury share repurchases	(94)			$ (94)
Net income	38,058					38,058
Comprehensive income (loss)	3,497				3,497
Common stock, ending balance (in shares) at Dec. 31, 2019		53,779,000
Equity, ending balance at Dec. 31, 2019	$ 1,156,494	$ 537	$ 485,838	$ (110,878)	$ (26,058)	$ 807,055
Treasury stock, ending balance (in shares) at Dec. 31, 2019	3,525,000			3,525,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Activities
Net income	$ 105,235	$ 103,474
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	21,664	24,253
Gain on divestiture	0	(1,284)
Loss on disposal of property and equipment	184	197
Deferred income taxes	7,383	3,309
Amortization of debt origination costs	2,766	4,543
Stock-based compensation costs	5,682	6,160
Loss on extinguishment of debt	2,155	0
Non-cash operating lease cost	6,117	0
Interest expense relating to ROU assets	34	0
Other	0	247
Changes in operating assets and liabilities:
Accounts receivable	4,624	5,398
Inventories	(817)	(11,081)
Prepaid expenses and other current assets	(879)	4,073
Accounts payable	(6,091)	(12,787)
Accrued liabilities	20,724	13,260
Operating lease liabilities	(6,430)	0
Other	(1,353)	(1,325)
Net cash provided by operating activities	160,998	138,437
Investing Activities
Purchases of property, plant and equipment	(9,055)	(7,139)
Escrow receipt	750	0
Proceeds from divestiture	0	65,912
Net cash (used in) provided by investing activities	(8,305)	58,773
Financing Activities
Proceeds from issuance of 5.125% Senior Notes	400,000	0
Repayment of 5.375% Senior Notes	(400,000)	0
Term loan repayments	(21,000)	(155,000)
Borrowings under revolving credit agreement	45,000	45,000
Repayments under revolving credit agreement	(120,000)	(45,000)
Payment of debt costs	(5,793)	0
Payments of finance leases	(252)	0
Proceeds from exercise of stock options	1,007	2,931
Fair value of shares surrendered as payment of tax withholding	(974)	(2,281)
Repurchase of common stock	(49,976)	(49,978)
Net cash used in financing activities	(151,988)	(204,328)
Effects of exchange rate changes on cash and cash equivalents	356	(758)
Increase in cash and cash equivalents	1,061	(7,876)
Cash and cash equivalents - beginning of period	27,530	32,548
Cash and cash equivalents - end of period	28,591	24,672
Interest paid	66,305	69,955
Income taxes paid	$ 21,212	$ 24,404

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 21,475	$ 12,965
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,779,000	53,670,000
Treasury stock (in shares)	3,525,000	1,871,000

Condensed Consolidated Cash Flo

Condensed Consolidated Cash Flows (Parenthetical)	Dec. 31, 2019	Dec. 02, 2019
2013 Senior Notes
Debt instrument, stated interest rate	5.375%
2013 Senior Notes | Senior Notes
Debt instrument, stated interest rate	5.375%
2019 Senior Notes
Debt instrument, stated interest rate		5.125%
2019 Senior Notes | Senior Notes
Debt instrument, stated interest rate	5.125%

Business and Basis of Presentat

Business and Basis of Presentation	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Consumer Healthcare Inc. (referred to herein as the “Company” or “we,” which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Consumer Healthcare Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products (prior to the sale of our Household Cleaning segment, as discussed in Note 2) to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada), and in Australia and certain other international markets. Prestige Consumer Healthcare Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 8. Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2020) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the nine months ended December 31, 2019 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2020. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2019. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions. Cash and Cash Equivalents We had non-cash financing activities in 2020 of $0.8 million relating to the December 2019 debt refinancing (see Note 8 for further details). Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). This update amended a number of aspects of lease accounting, including requiring lessees to recognize all leases with a term greater than one year as a right-of-use ("ROU") asset and corresponding lease liability, measured at the present value of the lease payments. On April 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for the three and nine months ended December 31, 2019 are presented under Topic 842. No prior period amounts were adjusted and the prior period continues to be reported in accordance with previous lease guidance, Accounting Standards Codification ("ASC") Topic 840, Leases . The new standard provided a number of optional practical expedients in transition. We elected the package of transition provisions available for expired or existing contracts, which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697) $ (5,697) Long-term operating lease liabilities, net of current portion $ — $ (13,296) $ (13,296) Other accrued liabilities (1) $ (60,663) $ 1,558 $ (59,105) (1) Relates to deferred rent and exit costs associated with existing leases. Adoption of this accounting pronouncement had no impact on our other financial statements. See Note 6 for our lease accounting policy. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. These amendments clarify and improve areas of guidance related to recently issued standards on the topics of credit losses, hedging and recognition and measurements. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief , which provides entities that have certain instruments an option to irrevocably elect the fair value option in Subtopic 825-10. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326 - Financial Instruments - Credit Losses , which clarifies guidance on how to report expected recoveries. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The amendments in this update eliminate the need for an organization to analyze whether certain exceptions apply for tax purposes. It also simplifies GAAP for certain taxes. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Divestitures

Divestitures	9 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Divestitures	DivestituresOn July 2, 2018, we sold the Comet®, Spic and Span®, Chore Boy®, Chlorinol® and Cinch® brands, as well as associated inventory. These brands represented our Household Cleaning segment. As a result of this transaction, we received proceeds of approximately $65.9 million and recorded a pre-tax gain on sale of $1.3 million. The net proceeds were used to repay debt.

Inventories

Inventories	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) December 31, 2019 March 31, 2019 Components of Inventories Packaging and raw materials $ 10,356 $ 17,082 Work in process 309 161 Finished goods 110,698 102,637 Inventories $ 121,363 $ 119,880

Goodwill

Goodwill	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2019 Goodwill $ 711,104 $ 31,190 $ 742,294 Accumulated impairment loss (163,711) — (163,711) Balance - March 31, 2019 547,393 31,190 578,583 2020 Reductions: Goodwill (1) (750) — (750) Effects of foreign currency exchange rates — (198) (198) Balance - December 31, 2019 Goodwill 710,354 30,992 741,346 Accumulated impairment loss (163,711) — (163,711) Balance - December 31, 2019 $ 546,643 $ 30,992 $ 577,635 (1) Amount relates to cash received from escrow associated with our acquisition of C.B. Fleet Company, Inc. ("Fleet"). On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. The date of our annual impairment review was February 28, 2019, and we recorded impairment charges in our March 31, 2019 financial statements. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 28, 2019, which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increasing competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an additional impairment charge to be recorded in the future. As of December 31, 2019, no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Intangible Assets, net A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (925) (25) (950) Balance — December 31, 2019 2,272,266 390,258 2,662,524 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 14,725 14,725 Effects of foreign currency exchange rates — (4) (4) Balance — December 31, 2019 — 170,985 170,985 Intangible assets, net - December 31, 2019 $ 2,272,266 $ 219,273 $ 2,491,539 Amortization expense was $4.9 million and $14.7 million for the three and nine months ended December 31, 2019, respectively, and $5.3 million and $16.5 million for the three and nine months ended December 31, 2018, respectively. Based on our amortizable intangible assets as of December 31, 2019, amortization expense is expected to be approximately $4.9 million for the remainder of fiscal 2020, $19.6 million in each of fiscal 2021, 2022, 2023 and 2024 and $136.0 million thereafter. Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. The date of our annual impairment review was February 28, 2019, and we recorded impairment charges in our March 31, 2019 financial statements. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. The discount rate utilized in the analyses, as well as future cash flows, may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of intangible assets be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, we may be required to record impairment charges in the future.

Leases

Leases	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	Leases We lease real estate and equipment for use in our operations. These leases have lease terms of 1 to 10 years, some of which include options to terminate or extend leases for up to 1 to 6 years or on a month-to-month basis. The exercise of lease renewal options is at our sole discretion and our lease ROU assets and liabilities reflect only the options we are reasonably certain that we will exercise. We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether we have the right to control the identified asset. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. Variable lease payments, which do not vary based on an index or rate, are excluded from the ROU asset and lease liability determination. Variable lease payments are typically usage-based and are recorded in the period in which the obligation for those payments is incurred. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. As the implicit rate in our leases is unknown, we used our incremental borrowing rate based on the information available at the date of adoption for existing leases and at the lease commencement date for new leases in determining the present value of future lease payments. We give consideration to our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rates. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. For the measurement and classification of our lease agreements, we group lease and non-lease components into a single lease component for all underlying asset classes. We have also elected to exclude any leases within our existing classes of assets with a term of twelve months or less. The components of lease expense for the three and nine months ended December 31, 2019 were as follows: (In thousands) Three Months Ended December 31, 2019 Nine Months Ended December 31, 2019 Finance lease cost: Amortization of right-of-use assets $ 207 $ 207 Interest on lease liabilities 34 34 Operating lease cost 2,239 5,697 Short term lease cost 28 78 Variable lease cost 15,731 48,396 Sublease income (833) (2,607) Total net lease cost $ 17,406 $ 51,805 As of December 31, 2019, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Financing Lease Total 2020 (Remaining three months ending March 31, 2020) $ 2,400 $ 336 $ 2,736 2021 7,073 1,342 8,415 2022 6,551 1,342 7,893 2023 6,307 1,342 7,649 2024 6,294 1,342 7,636 Thereafter 9,095 672 9,767 Total undiscounted lease payments 37,720 6,376 44,096 Less amount of lease payments representing interest (5,143) (492) (5,635) Total present value of lease payments $ 32,577 $ 5,884 $ 38,461 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2019 Weighted average remaining lease term (years) Operating leases 5.49 Financing leases 4.75 Weighted average discount rate Operating leases 5.27 % Financing leases 3.49 % The following table summarizes future minimum lease payments for our operating leases as of March 31, 2019, before adoption of Topic 842: (In thousands) Facilities Equipment Total Year Ending March 31, 2020 $ 2,828 $ 314 $ 3,142 2021 2,633 248 2,881 2022 2,265 213 2,478 2023 1,684 105 1,789 2024 1,705 — 1,705 Thereafter 6,780 — 6,780 $ 17,895 $ 880 $ 18,775 five
Leases	Leases We lease real estate and equipment for use in our operations. These leases have lease terms of 1 to 10 years, some of which include options to terminate or extend leases for up to 1 to 6 years or on a month-to-month basis. The exercise of lease renewal options is at our sole discretion and our lease ROU assets and liabilities reflect only the options we are reasonably certain that we will exercise. We determine if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether we have the right to control the identified asset. ROU assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. Variable lease payments, which do not vary based on an index or rate, are excluded from the ROU asset and lease liability determination. Variable lease payments are typically usage-based and are recorded in the period in which the obligation for those payments is incurred. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. As the implicit rate in our leases is unknown, we used our incremental borrowing rate based on the information available at the date of adoption for existing leases and at the lease commencement date for new leases in determining the present value of future lease payments. We give consideration to our credit risk, term of the lease, total lease payments and adjust for the impacts of collateral, as necessary, when calculating our incremental borrowing rates. Rent expense for our operating leases is recognized on a straight-line basis over the lease term. For the measurement and classification of our lease agreements, we group lease and non-lease components into a single lease component for all underlying asset classes. We have also elected to exclude any leases within our existing classes of assets with a term of twelve months or less. The components of lease expense for the three and nine months ended December 31, 2019 were as follows: (In thousands) Three Months Ended December 31, 2019 Nine Months Ended December 31, 2019 Finance lease cost: Amortization of right-of-use assets $ 207 $ 207 Interest on lease liabilities 34 34 Operating lease cost 2,239 5,697 Short term lease cost 28 78 Variable lease cost 15,731 48,396 Sublease income (833) (2,607) Total net lease cost $ 17,406 $ 51,805 As of December 31, 2019, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Financing Lease Total 2020 (Remaining three months ending March 31, 2020) $ 2,400 $ 336 $ 2,736 2021 7,073 1,342 8,415 2022 6,551 1,342 7,893 2023 6,307 1,342 7,649 2024 6,294 1,342 7,636 Thereafter 9,095 672 9,767 Total undiscounted lease payments 37,720 6,376 44,096 Less amount of lease payments representing interest (5,143) (492) (5,635) Total present value of lease payments $ 32,577 $ 5,884 $ 38,461 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2019 Weighted average remaining lease term (years) Operating leases 5.49 Financing leases 4.75 Weighted average discount rate Operating leases 5.27 % Financing leases 3.49 % The following table summarizes future minimum lease payments for our operating leases as of March 31, 2019, before adoption of Topic 842: (In thousands) Facilities Equipment Total Year Ending March 31, 2020 $ 2,828 $ 314 $ 3,142 2021 2,633 248 2,881 2022 2,265 213 2,478 2023 1,684 105 1,789 2024 1,705 — 1,705 Thereafter 6,780 — 6,780 $ 17,895 $ 880 $ 18,775 five

Other Accrued Liabilities

Other Accrued Liabilities	9 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) December 31, 2019 March 31, 2019 Accrued marketing costs $ 36,774 $ 31,228 Accrued compensation costs 8,906 10,958 Accrued broker commissions 1,462 1,361 Income taxes payable 6,216 88 Accrued professional fees 4,145 2,441 Accrued production costs 8,092 6,788 Other accrued liabilities 11,015 7,799 $ 76,610 $ 60,663

Long-Term Debt

Long-Term Debt	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term DebtAt December 31, 2019, we had no balance outstanding on the asset-based revolving credit facility entered into January 31, 2012, as amended (the "2012 ABL Revolver") and a borrowing capacity of $153.3 million. Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2019 March 31, 2019 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes were due to mature on December 15, 2021, and were redeemed on December 2, 2019. — 400,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 — 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a base rate floor of 1.00%, due on January 26, 2024. 717,000 738,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on December 11, 2024. — 75,000 Long-term debt 1,717,000 1,813,000 Less: unamortized debt costs (15,687) (14,402) Long-term debt, net $ 1,701,313 $ 1,798,598 New Debt Issuance and Redemption: On December 2, 2019, we issued $400.0 million aggregate principal amount of 5.125% senior notes ("2019 Senior Notes") pursuant to an indenture dated December 2, 2019, among Prestige Brands, Inc., the guarantors party thereto (including the Company) and the U.S. Bank National Association, as a trustee. The 2019 Senior Notes mature on January 15, 2028. We used the net proceeds from the 2019 Senior Notes, together with cash on hand, to redeem all $400.0 million of our outstanding 5.375% 2013 Senior Notes, which were due in 2021, and to pay related fees and expenses. In conjunction with the redemption of our 5.375% 2013 Senior Notes, we wrote off related debt costs of $2.2 million. 2012 ABL Revolver: On December 11, 2019, the Company and Prestige Brands, Inc. entered into Amendment No. 7 ("ABL Amendment No. 7") to the 2012 ABL Revolver. ABL Amendment No. 7 provides for (i) an extension of the maturity date of the revolving credit facility to five years from the effective date of the amendment, (ii) increased flexibility under the 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility, (iii) an initial applicable margin for borrowings under the 2012 ABL Revolver that is 1.00% with respect to LIBOR borrowings and 0.00% with respect to base-rate borrowings (which may be increased to 1.25% or 1.50% for LIBOR borrowings and 0.25% or 0.50% for base-rate borrowings, depending on average excess availability under the facility during the prior fiscal quarter) and (iv) a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder of 0.25% per annum. As of December 31, 2019, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 2019 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2020 (remaining three months ending March 31, 2020) $ — 2021 — 2022 — 2023 — 2024 1,317,000 Thereafter 400,000 $ 1,717,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. FASB ASC 820, Fair Value Measurements , requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. ASC 820 established market (observable inputs) as the preferred source of fair value, to be followed by our assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by us using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2019 Senior Notes, the 2012 Term B-5 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy. See summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2019 and March 31, 2019. December 31, 2019 March 31, 2019 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 623,250 $ 600,000 $ 606,000 2013 Senior Notes — — 400,000 401,500 2019 Senior Notes 400,000 418,000 — — 2012 Term B-5 Loans 717,000 720,585 738,000 728,775 2012 ABL Revolver — — 75,000 75,000

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity We are authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on our common stock through December 31, 2019. During the three and nine months ended December 31, 2019, we repurchased 2,481 shares and 31,018 shares, respectively, of common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the three and nine months ended December 31, 2019 were at an average price of $37.95 and $31.39 per share, respectively. During the three months ended December 31, 2018, we made no repurchases of common stock. During the nine months ended December 31, 2018, we repurchased 68,939 shares of common stock from our employees pursuant to the provisions of various employee restricted stock awards at an average price of $33.09 per share. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Accumulated other comprehensive loss consisted of the following at December 31, 2019 and March 31, 2019: (In thousands) December 31, 2019 March 31, 2019 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (27,189) $ (26,878) Unrecognized net gain on pension plans, net of tax of $0.3 million and $0.3 million, respectively 1,131 1,131 Accumulated other comprehensive loss, net of tax $ (26,058) $ (25,747)

Earnings Per Share

Earnings Per Share	9 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on income available to common stockholders and the weighted average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units ("RSUs"). Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and nonvested RSUs, are included in the diluted earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and RSUs has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2019 2018 2019 2018 Numerator Net income $ 38,058 $ 38,167 $ 105,235 $ 103,474 Denominator Denominator for basic earnings per share — weighted average shares outstanding 50,378 51,881 50,840 52,119 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 453 321 386 312 Denominator for diluted earnings per share 50,831 52,202 51,226 52,431 Earnings per Common Share: Basic earnings per share $ 0.76 $ 0.74 $ 2.07 $ 1.99 Diluted earnings per share $ 0.75 $ 0.73 $ 2.05 $ 1.97

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, RSUs and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, our stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, an increase of the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any fiscal 12-month period from 1.0 million to 2.5 million shares, and an extension of the term of the Plan by ten During the three and nine months ended December 31, 2019, pre-tax share-based compensation costs charged against income were $1.8 million and $5.7 million, respectively, and the related income tax benefit recognized was $0.3 million and $0.9 million, respectively. During the three and nine months ended December 31, 2018, pre-tax share-based compensation costs charged against income were $1.9 million and $6.2 million, respectively, and the related income tax benefit recognized was $0.3 million and $1.1 million, respectively. At December 31, 2019, there were $7.5 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted average period of 1.0 year. The total fair value of options and RSUs vested during the nine months ended December 31, 2019 and 2018 was $7.8 million and $12.0 million, respectively. For the nine months ended December 31, 2019 and 2018, we received cash from the exercise of stock options of $1.0 million and $2.9 million, respectively. For the nine months ended December 31, 2019 and 2018, we realized $0.6 million and $1.3 million, respectively, in tax benefits from the tax deductions resulting from RSU issuances and stock option exercises. At December 31, 2019, there were 1.5 million shares available for issuance under the Plan. On May 6, 2019, the Compensation and Talent Management Committee of our Board of Directors granted 98,644 performance stock units, 89,286 RSUs and stock options to acquire 281,487 shares of our common stock under the Plan to certain executive officers and employees. The stock options were granted at an exercise price of $30.56 per share, which was equal to the closing price for our common stock on the date of the grant. On May 13, 2019, the Compensation and Talent Management Committee of our Board of Directors granted 7,287 RSUs and stock options to acquire 21,194 shares of our common stock under the Plan to a recently hired executive officer. The stock options were granted at an exercise price of $30.19 per share, which was equal to the closing price for our common stock on the date of the grant. Each of the independent members of the Board of Directors received a grant under the Plan of 4,183 RSUs on July 30, 2019. Restricted Stock Units RSUs granted to employees under the Plan generally vest in three three three six The fair value of the RSUs is determined using the closing price of our common stock on the date of the grant. A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 226.4 30.09 Vested and issued (175.8) 43.05 Forfeited (31.1) 48.32 Vested and nonvested at December 31, 2018 413.0 36.58 Vested at December 31, 2018 113.2 31.05 Nine Months Ended December 31, 2019 Vested and nonvested at March 31, 2019 413.0 $ 36.58 Granted 220.3 31.02 Vested and issued (73.0) 47.68 Forfeited (34.2) 35.97 Vested and nonvested at December 31, 2019 526.1 32.74 Vested at December 31, 2019 138.3 31.71 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of our common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three five The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted average grant-date fair values of the options granted during the nine months ended December 31, 2019 and 2018 were $10.83 and $10.22, respectively. Nine Months Ended December 31, 2019 2018 Expected volatility 30.9% - 31.3% 29.6 % Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 Risk-free rate 2.3% to 2.4% 2.9 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (97.7) 30.02 Forfeited or expired (125.4) 47.16 Outstanding at December 31, 2018 944.6 38.45 7.2 $ 2,477 Vested at December 31, 2018 499.4 37.87 5.8 $ 2,076 Nine Months Ended December 31, 2019 Outstanding at March 31, 2019 944.6 $ 38.45 Granted 302.7 30.53 Exercised (36.0) 27.96 Forfeited or expired (155.3) 41.18 Outstanding at December 31, 2019 1,056.0 36.14 6.9 $ 9,035 Vested at December 31, 2019 602.0 38.90 5.4 $ 4,756 The aggregate intrinsic value of options exercised during the nine months ended December 31, 2019 was $0.3 million.

Income Taxes

Income Taxes	9 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates were 24.7% and 25.2% for the three months ended December 31, 2019 and 2018, respectively.  The effective tax rates were 25.2% and 26.6% for the nine months ended December 31, 2019 and 2018, respectively. The decrease in the effective tax rate for the nine months ended December 31, 2019 versus the prior year period was primarily related to a discrete item arising from the sale of our Household Cleaning segment in July 2018.In the second quarter of 2020, we revised the Condensed Consolidated Statements of Cash Flows to correct an error in the disclosed amount of income taxes paid in the six months ended September 30, 2018. The correction increased income taxes paid in the nine months ended December 31, 2018 from the previously reported amount of $19.1 million to $24.4 million. We have evaluated the impact of this error and determined it is not material to the previously issued financial statements.

Employee Retirement Plans

Employee Retirement Plans	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Employee Retirement Plans	Employee Retirement Plans The primary components of Net Periodic Benefits consist of the following: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2019 2018 2019 2018 Interest cost $ 575 $ 599 $ 1,729 $ 1,819 Expected return on assets (722) (767) (2,164) (2,303) Net periodic benefit income $ (147) $ (168) $ (435) $ (484) During the nine months ended December 31, 2019, we contributed $0.3 million to our non-qualified defined benefit plan and $1.0 million to the qualified defined benefit plan. During the remainder of fiscal 2020, we expect to contribute an additional $0.1 million to our non-qualified plan and make no further contributions to the qualified plan.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and ContingenciesWe are involved from time to time in legal matters and other claims incidental to our business.  We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss.  These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted.  The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations.

Concentrations of Risk

Concentrations of Risk	9 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the area of OTC Healthcare. We sell our products to mass merchandisers and drug, food, dollar, convenience and club stores and e-commerce channels. During both the three months ended December 31, 2019 and 2018, approximately 41.7% of our gross revenues were derived from our five top selling brands. During both the nine months ended December 31, 2019 and 2018, approximately 42.8% of our gross revenues were derived from our five top selling brands. One customer, Walmart accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 23.2% and 23.4% of our gross revenues for the three and nine months ended December 31, 2019, respectively. Walmart accounted for approximately 22.3% and 23.5% of our gross revenues for the three and nine months ended December 31, 2018, respectively. The gross revenues for Walmart are included in our North American OTC Healthcare segment and Household Cleaning segment (prior to the sale of our Household Cleaning segment on July 2, 2018). Our product distribution in the United States is managed by a third party through one primary distribution center near St. Louis, Missouri. In May 2019, we entered into an agreement with a second third party logistics provider for a warehouse, and we are in the process of transitioning to this facility, which is managed by a new logistics provider. In addition, we operate one manufacturing facility for certain of our products located in Lynchburg, Virginia. A serious disruption, caused by performance or contractual issues with a third party distribution manager or by natural disaster, such as earthquake, flood, or fire, could damage our inventory and/or materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. Any disruption as a result of business integration, transition of our distribution center to the new third party manager or new location, or third party performance at our distribution centers, could result in increased costs, expense and/or shipping times, and could cause us to incur customer fees and penalties. In addition, any serious disruption to our Lynchburg manufacturing facility could materially impair our ability to manufacture many of the products associated with our acquisition of Fleet, which would also limit our ability to provide those products to customers in a timely manner or at a reasonable cost. We could also incur significantly higher costs and experience longer lead times if we need to replace our distribution centers, the third party distribution managers or the manufacturing facility. As a result, any serious disruption could have a material adverse effect on our business, financial condition and results of operations. At December 31, 2019, we had relationships with 113 third party manufacturers. Of those, we had long-term contracts with 17 manufacturers that produced items that accounted for approximately 66.2% of gross sales for the nine months ended December 31, 2019. At December 31, 2018, we had relationships with 112 third party manufacturers. Of those, we had long-term contracts with 33 manufacturers that produced items that accounted for approximately 60.4% of gross sales for the nine months ended December 31, 2018. The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results of operations. Although we are continually in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	9 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare and (ii) International OTC Healthcare. We sold our Household Cleaning segment on July 2, 2018; see Note 2 for further information. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 214,892 $ 26,660 $ — $ 241,552 Cost of sales 93,937 10,120 — 104,057 Gross profit 120,955 16,540 — 137,495 Advertising and promotion 29,025 4,534 — 33,559 Contribution margin $ 91,930 $ 12,006 $ — 103,936 Other operating expenses 27,532 Operating income 76,404 Other expense 25,850 Income before income taxes 50,554 Provision for income taxes 12,496 Net income $ 38,058 * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 639,554 $ 72,221 $ — $ 711,775 Cost of sales 275,679 27,783 — 303,462 Gross profit 363,875 44,438 — 408,313 Advertising and promotion 94,634 12,393 — 107,027 Contribution margin $ 269,241 $ 32,045 $ — 301,286 Other operating expenses 84,048 Operating income 217,238 Other expense 76,622 Income before income taxes 140,616 Provision for income taxes 35,381 Net income $ 105,235 * Intersegment revenues of $2.1 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 216,776 $ 24,638 $ — $ 241,414 Cost of sales 91,594 10,585 — 102,179 Gross profit 125,182 14,053 — 139,235 Advertising and promotion 30,316 4,188 — 34,504 Contribution margin $ 94,866 $ 9,865 $ — 104,731 Other operating expenses 27,190 Operating income 77,541 Other expense 26,545 Income before income taxes 50,996 Provision for income taxes 12,829 Net income $ 38,167 * Intersegment revenues of $1.3 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 647,501 $ 67,439 $ 19,811 $ 734,751 Cost of sales 272,754 28,079 16,588 317,421 Gross profit 374,747 39,360 3,223 417,330 Advertising and promotion 96,899 11,328 430 108,657 Contribution margin $ 277,848 $ 28,032 $ 2,793 308,673 Other operating expenses 87,721 Operating income 220,952 Other expense 79,977 Income before income taxes 140,975 Provision for income taxes 37,501 Net income $ 103,474 * Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,330 $ 175 $ — $ 28,505 Cough & Cold 25,221 4,742 — 29,963 Women's Health 58,576 3,543 — 62,119 Gastrointestinal 32,645 12,097 — 44,742 Eye & Ear Care 24,095 3,159 — 27,254 Dermatologicals 23,286 598 — 23,884 Oral Care 21,451 2,344 — 23,795 Other OTC 1,288 2 — 1,290 Household Cleaning — — — — Total segment revenues $ 214,892 $ 26,660 $ — $ 241,552 Nine Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 85,696 $ 648 $ — $ 86,344 Cough & Cold 63,067 15,938 — 79,005 Women's Health 177,832 8,867 — 186,699 Gastrointestinal 96,431 28,110 — 124,541 Eye & Ear Care 73,134 9,355 — 82,489 Dermatologicals 77,063 1,864 — 78,927 Oral Care 62,493 7,435 — 69,928 Other OTC 3,838 4 — 3,842 Household Cleaning — — — — Total segment revenues $ 639,554 $ 72,221 $ — $ 711,775 Three Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,325 $ 136 $ — $ 29,461 Cough & Cold 27,137 4,584 — 31,721 Women's Health 60,946 3,306 — 64,252 Gastrointestinal 30,737 10,321 — 41,058 Eye & Ear Care 23,352 3,164 — 26,516 Dermatologicals 21,508 470 — 21,978 Oral Care 22,177 2,656 — 24,833 Other OTC 1,594 1 — 1,595 Household Cleaning — — — — Total segment revenues $ 216,776 $ 24,638 $ — $ 241,414 Nine Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,221 $ 418 $ — $ 86,639 Cough & Cold 63,843 15,489 — 79,332 Women's Health 186,037 8,833 — 194,870 Gastrointestinal 94,065 24,261 — 118,326 Eye & Ear Care 73,669 8,778 — 82,447 Dermatologicals 71,968 1,607 — 73,575 Oral Care 67,516 8,050 — 75,566 Other OTC 4,182 3 — 4,185 Household Cleaning — — 19,811 19,811 Total segment revenues $ 647,501 $ 67,439 $ 19,811 $ 734,751 Our total segment revenues by geographic area are as follows: Three Months Ended December 31, Nine Months Ended December 31, 2019 2018 2019 2018 United States $ 203,920 204,943 $ 604,263 $ 632,183 Rest of world 37,632 36,471 107,512 102,568 Total $ 241,552 $ 241,414 $ 711,775 $ 734,751 Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: December 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 546,643 $ 30,992 $ 577,635 Intangible assets Indefinite-lived 2,195,616 76,650 2,272,266 Finite-lived, net 214,390 4,883 219,273 Intangible assets, net 2,410,006 81,533 2,491,539 Total $ 2,956,649 $ 112,525 $ 3,069,174 March 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 31,190 $ 578,583 Intangible assets Indefinite-lived 2,195,617 77,574 2,273,191 Finite-lived, net 228,743 5,276 234,019 Intangible assets, net 2,424,360 82,850 2,507,210 Total $ 2,971,753 $ 114,040 $ 3,085,793

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Condensed Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, these Condensed Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Condensed Consolidated Financial Statements or related notes to a year (e.g., 2020) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the nine months ended December 31, 2019 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2020. These unaudited Condensed Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2019.
Use of Estimates	Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.  Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. Our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances, inventory obsolescence, and accounting for income taxes and related uncertain tax positions.
Cash and Cash Equivalents	Cash and Cash Equivalents We had non-cash financing activities in 2020 of $0.8 million relating to the December 2019 debt refinancing (see Note 8 for further details).
Recently Adopted and Issued Accounting Standards	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842). This update amended a number of aspects of lease accounting, including requiring lessees to recognize all leases with a term greater than one year as a right-of-use ("ROU") asset and corresponding lease liability, measured at the present value of the lease payments. On April 1, 2019, we adopted Topic 842 using the modified retrospective approach. Results for the three and nine months ended December 31, 2019 are presented under Topic 842. No prior period amounts were adjusted and the prior period continues to be reported in accordance with previous lease guidance, Accounting Standards Codification ("ASC") Topic 840, Leases . The new standard provided a number of optional practical expedients in transition. We elected the package of transition provisions available for expired or existing contracts, which allowed us to carryforward our historical assessments of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697) $ (5,697) Long-term operating lease liabilities, net of current portion $ — $ (13,296) $ (13,296) Other accrued liabilities (1) $ (60,663) $ 1,558 $ (59,105) (1) Relates to deferred rent and exit costs associated with existing leases. Adoption of this accounting pronouncement had no impact on our other financial statements. See Note 6 for our lease accounting policy. Recently Issued Accounting Pronouncements In August 2018, the FASB issued ASU 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20): Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. The amendments in this update modify the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by eliminating certain required disclosures and incorporating others. The amendments are effective for public companies for fiscal years ending after December 15, 2020. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this update modify the disclosure requirements in Topic 820, with a particular focus on Level 3 investments, by eliminating certain required disclosures and incorporating others. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. We do not expect the adoption of this standard to have a material impact on our Consolidated Financial Statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments . The amendments in this update provide financial statement users with more useful information about expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. In April 2019, the FASB issued ASU 2019-04, Codification Improvements to Topic 326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. These amendments clarify and improve areas of guidance related to recently issued standards on the topics of credit losses, hedging and recognition and measurements. In May 2019, the FASB issued ASU 2019-05, Financial Instruments - Credit Losses (Topic 326): Targeted Transition Relief , which provides entities that have certain instruments an option to irrevocably elect the fair value option in Subtopic 825-10. In November 2019, the FASB issued ASU 2019-11, Codification Improvements to Topic 326 - Financial Instruments - Credit Losses , which clarifies guidance on how to report expected recoveries. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes . The amendments in this update eliminate the need for an organization to analyze whether certain exceptions apply for tax purposes. It also simplifies GAAP for certain taxes. The amendments in these updates are effective for us for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. We are currently evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Business and Basis of Present_3

Business and Basis of Presentation (Tables)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Effects of Recently Adopted Accounting Pronouncement	The effects of this recently adopted accounting pronouncement to our Consolidated Balance Sheet as of April 1, 2019 are as follows: (In thousands) March 31, 2019 New Lease Standard Adjustment April 1, 2019 Assets: Operating lease ROU assets $ — $ 17,435 $ 17,435 Liabilities: Operating lease liabilities, current portion $ — $ (5,697) $ (5,697) Long-term operating lease liabilities, net of current portion $ — $ (13,296) $ (13,296) Other accrued liabilities (1) $ (60,663) $ 1,558 $ (59,105) (1) Relates to deferred rent and exit costs associated with existing leases.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) December 31, 2019 March 31, 2019 Components of Inventories Packaging and raw materials $ 10,356 $ 17,082 Work in process 309 161 Finished goods 110,698 102,637 Inventories $ 121,363 $ 119,880

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC International OTC Consolidated Balance - March 31, 2019 Goodwill $ 711,104 $ 31,190 $ 742,294 Accumulated impairment loss (163,711) — (163,711) Balance - March 31, 2019 547,393 31,190 578,583 2020 Reductions: Goodwill (1) (750) — (750) Effects of foreign currency exchange rates — (198) (198) Balance - December 31, 2019 Goodwill 710,354 30,992 741,346 Accumulated impairment loss (163,711) — (163,711) Balance - December 31, 2019 $ 546,643 $ 30,992 $ 577,635 (1) Amount relates to cash received from escrow associated with our acquisition of C.B. Fleet Company, Inc. ("Fleet").

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Finite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (925) (25) (950) Balance — December 31, 2019 2,272,266 390,258 2,662,524 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 14,725 14,725 Effects of foreign currency exchange rates — (4) (4) Balance — December 31, 2019 — 170,985 170,985 Intangible assets, net - December 31, 2019 $ 2,272,266 $ 219,273 $ 2,491,539
Reconciliation of the Activity Affecting Indefinite Lived Intangible Assets	A reconciliation of the activity affecting intangible assets, net is as follows: (In thousands) Indefinite- Finite-Lived Totals Gross Carrying Amounts Balance — March 31, 2019 $ 2,273,191 $ 390,283 $ 2,663,474 Effects of foreign currency exchange rates (925) (25) (950) Balance — December 31, 2019 2,272,266 390,258 2,662,524 Accumulated Amortization Balance — March 31, 2019 — 156,264 156,264 Additions — 14,725 14,725 Effects of foreign currency exchange rates — (4) (4) Balance — December 31, 2019 — 170,985 170,985 Intangible assets, net - December 31, 2019 $ 2,272,266 $ 219,273 $ 2,491,539

Leases (Tables)

Leases (Tables)	9 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Components of Lease Expense	The components of lease expense for the three and nine months ended December 31, 2019 were as follows: (In thousands) Three Months Ended December 31, 2019 Nine Months Ended December 31, 2019 Finance lease cost: Amortization of right-of-use assets $ 207 $ 207 Interest on lease liabilities 34 34 Operating lease cost 2,239 5,697 Short term lease cost 28 78 Variable lease cost 15,731 48,396 Sublease income (833) (2,607) Total net lease cost $ 17,406 $ 51,805 The weighted average remaining lease term and weighted average discount rate were as follows: December 31, 2019 Weighted average remaining lease term (years) Operating leases 5.49 Financing leases 4.75 Weighted average discount rate Operating leases 5.27 % Financing leases 3.49 %
Maturities of Operating Leases	As of December 31, 2019, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Financing Lease Total 2020 (Remaining three months ending March 31, 2020) $ 2,400 $ 336 $ 2,736 2021 7,073 1,342 8,415 2022 6,551 1,342 7,893 2023 6,307 1,342 7,649 2024 6,294 1,342 7,636 Thereafter 9,095 672 9,767 Total undiscounted lease payments 37,720 6,376 44,096 Less amount of lease payments representing interest (5,143) (492) (5,635) Total present value of lease payments $ 32,577 $ 5,884 $ 38,461
Maturities of Finance Leases	As of December 31, 2019, the maturities of lease liabilities were as follows: (In thousands) Year Ending March 31, Operating Leases Financing Lease Total 2020 (Remaining three months ending March 31, 2020) $ 2,400 $ 336 $ 2,736 2021 7,073 1,342 8,415 2022 6,551 1,342 7,893 2023 6,307 1,342 7,649 2024 6,294 1,342 7,636 Thereafter 9,095 672 9,767 Total undiscounted lease payments 37,720 6,376 44,096 Less amount of lease payments representing interest (5,143) (492) (5,635) Total present value of lease payments $ 32,577 $ 5,884 $ 38,461
Future Minimum Rental Payments for Operating Leases Under Prior Guidance	The following table summarizes future minimum lease payments for our operating leases as of March 31, 2019, before adoption of Topic 842: (In thousands) Facilities Equipment Total Year Ending March 31, 2020 $ 2,828 $ 314 $ 3,142 2021 2,633 248 2,881 2022 2,265 213 2,478 2023 1,684 105 1,789 2024 1,705 — 1,705 Thereafter 6,780 — 6,780 $ 17,895 $ 880 $ 18,775

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Dec. 31, 2019
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) December 31, 2019 March 31, 2019 Accrued marketing costs $ 36,774 $ 31,228 Accrued compensation costs 8,906 10,958 Accrued broker commissions 1,462 1,361 Income taxes payable 6,216 88 Accrued professional fees 4,145 2,441 Accrued production costs 8,092 6,788 Other accrued liabilities 11,015 7,799 $ 76,610 $ 60,663

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) December 31, 2019 March 31, 2019 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 600,000 $ 600,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes were due to mature on December 15, 2021, and were redeemed on December 2, 2019. — 400,000 2019 Senior Notes bearing interest at 5.125%, with interest payable on January 15 and July 15 of each year. The 2019 Senior Notes mature on January 15, 2028. 400,000 — 2012 Term B-5 Loans bearing interest at the Borrower's option at either LIBOR plus a margin of 2.00%, with a LIBOR floor of 0.00%, or an alternate base rate plus a margin of 1.00%, with a base rate floor of 1.00%, due on January 26, 2024. 717,000 738,000 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on December 11, 2024. — 75,000 Long-term debt 1,717,000 1,813,000 Less: unamortized debt costs (15,687) (14,402) Long-term debt, net $ 1,701,313 $ 1,798,598
Aggregate Future Principal Payments	As of December 31, 2019, aggregate future principal payments required in accordance with the terms of the 2012 Term B-5 Loans, 2012 ABL Revolver and the indentures governing the 6.375% senior unsecured notes due 2024 (the "2016 Senior Notes") and the 2019 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2020 (remaining three months ending March 31, 2020) $ — 2021 — 2022 — 2023 — 2024 1,317,000 Thereafter 400,000 $ 1,717,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	See summary below detailing the carrying amounts and estimated fair values of these borrowings at December 31, 2019 and March 31, 2019. December 31, 2019 March 31, 2019 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 600,000 $ 623,250 $ 600,000 $ 606,000 2013 Senior Notes — — 400,000 401,500 2019 Senior Notes 400,000 418,000 — — 2012 Term B-5 Loans 717,000 720,585 738,000 728,775 2012 ABL Revolver — — 75,000 75,000

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consisted of the following at December 31, 2019 and March 31, 2019: (In thousands) December 31, 2019 March 31, 2019 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (27,189) $ (26,878) Unrecognized net gain on pension plans, net of tax of $0.3 million and $0.3 million, respectively 1,131 1,131 Accumulated other comprehensive loss, net of tax $ (26,058) $ (25,747)

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, (In thousands, except per share data) 2019 2018 2019 2018 Numerator Net income $ 38,058 $ 38,167 $ 105,235 $ 103,474 Denominator Denominator for basic earnings per share — weighted average shares outstanding 50,378 51,881 50,840 52,119 Dilutive effect of nonvested restricted stock units and options issued to employees and directors 453 321 386 312 Denominator for diluted earnings per share 50,831 52,202 51,226 52,431 Earnings per Common Share: Basic earnings per share $ 0.76 $ 0.74 $ 2.07 $ 1.99 Diluted earnings per share $ 0.75 $ 0.73 $ 2.05 $ 1.97

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Summary of Restricted Shares	A summary of the RSUs granted under the Plan is presented below: RSUs Shares (in thousands) Weighted Nine Months Ended December 31, 2018 Vested and nonvested at March 31, 2018 393.5 $ 44.13 Granted 226.4 30.09 Vested and issued (175.8) 43.05 Forfeited (31.1) 48.32 Vested and nonvested at December 31, 2018 413.0 36.58 Vested at December 31, 2018 113.2 31.05 Nine Months Ended December 31, 2019 Vested and nonvested at March 31, 2019 413.0 $ 36.58 Granted 220.3 31.02 Vested and issued (73.0) 47.68 Forfeited (34.2) 35.97 Vested and nonvested at December 31, 2019 526.1 32.74 Vested at December 31, 2019 138.3 31.71
Fair Value of Options Granted	The weighted average grant-date fair values of the options granted during the nine months ended December 31, 2019 and 2018 were $10.83 and $10.22, respectively. Nine Months Ended December 31, 2019 2018 Expected volatility 30.9% - 31.3% 29.6 % Expected dividends $ — $ — Expected term in years 6.0 to 7.0 6.0 Risk-free rate 2.3% to 2.4% 2.9 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted Weighted Aggregate Nine Months Ended December 31, 2018 Outstanding at March 31, 2018 873.2 $ 41.79 Granted 294.5 29.46 Exercised (97.7) 30.02 Forfeited or expired (125.4) 47.16 Outstanding at December 31, 2018 944.6 38.45 7.2 $ 2,477 Vested at December 31, 2018 499.4 37.87 5.8 $ 2,076 Nine Months Ended December 31, 2019 Outstanding at March 31, 2019 944.6 $ 38.45 Granted 302.7 30.53 Exercised (36.0) 27.96 Forfeited or expired (155.3) 41.18 Outstanding at December 31, 2019 1,056.0 36.14 6.9 $ 9,035 Vested at December 31, 2019 602.0 38.90 5.4 $ 4,756

Employee Retirement Plans (Tabl

Employee Retirement Plans (Tables)	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of Primary Components of Net Periodic Benefits	The primary components of Net Periodic Benefits consist of the following: Three Months Ended December 31, Nine Months Ended December 31, (In thousands) 2019 2018 2019 2018 Interest cost $ 575 $ 599 $ 1,729 $ 1,819 Expected return on assets (722) (767) (2,164) (2,303) Net periodic benefit income $ (147) $ (168) $ (435) $ (484)

Business Segments (Tables)

Business Segments (Tables)	9 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 214,892 $ 26,660 $ — $ 241,552 Cost of sales 93,937 10,120 — 104,057 Gross profit 120,955 16,540 — 137,495 Advertising and promotion 29,025 4,534 — 33,559 Contribution margin $ 91,930 $ 12,006 $ — 103,936 Other operating expenses 27,532 Operating income 76,404 Other expense 25,850 Income before income taxes 50,554 Provision for income taxes 12,496 Net income $ 38,058 * Intersegment revenues of $0.6 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 639,554 $ 72,221 $ — $ 711,775 Cost of sales 275,679 27,783 — 303,462 Gross profit 363,875 44,438 — 408,313 Advertising and promotion 94,634 12,393 — 107,027 Contribution margin $ 269,241 $ 32,045 $ — 301,286 Other operating expenses 84,048 Operating income 217,238 Other expense 76,622 Income before income taxes 140,616 Provision for income taxes 35,381 Net income $ 105,235 * Intersegment revenues of $2.1 million were eliminated from the North American OTC Healthcare segment. Three Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 216,776 $ 24,638 $ — $ 241,414 Cost of sales 91,594 10,585 — 102,179 Gross profit 125,182 14,053 — 139,235 Advertising and promotion 30,316 4,188 — 34,504 Contribution margin $ 94,866 $ 9,865 $ — 104,731 Other operating expenses 27,190 Operating income 77,541 Other expense 26,545 Income before income taxes 50,996 Provision for income taxes 12,829 Net income $ 38,167 * Intersegment revenues of $1.3 million were eliminated from the North American OTC Healthcare segment. Nine Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Total segment revenues* $ 647,501 $ 67,439 $ 19,811 $ 734,751 Cost of sales 272,754 28,079 16,588 317,421 Gross profit 374,747 39,360 3,223 417,330 Advertising and promotion 96,899 11,328 430 108,657 Contribution margin $ 277,848 $ 28,032 $ 2,793 308,673 Other operating expenses 87,721 Operating income 220,952 Other expense 79,977 Income before income taxes 140,975 Provision for income taxes 37,501 Net income $ 103,474 * Intersegment revenues of $5.6 million were eliminated from the North American OTC Healthcare segment.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 28,330 $ 175 $ — $ 28,505 Cough & Cold 25,221 4,742 — 29,963 Women's Health 58,576 3,543 — 62,119 Gastrointestinal 32,645 12,097 — 44,742 Eye & Ear Care 24,095 3,159 — 27,254 Dermatologicals 23,286 598 — 23,884 Oral Care 21,451 2,344 — 23,795 Other OTC 1,288 2 — 1,290 Household Cleaning — — — — Total segment revenues $ 214,892 $ 26,660 $ — $ 241,552 Nine Months Ended December 31, 2019 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 85,696 $ 648 $ — $ 86,344 Cough & Cold 63,067 15,938 — 79,005 Women's Health 177,832 8,867 — 186,699 Gastrointestinal 96,431 28,110 — 124,541 Eye & Ear Care 73,134 9,355 — 82,489 Dermatologicals 77,063 1,864 — 78,927 Oral Care 62,493 7,435 — 69,928 Other OTC 3,838 4 — 3,842 Household Cleaning — — — — Total segment revenues $ 639,554 $ 72,221 $ — $ 711,775 Three Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,325 $ 136 $ — $ 29,461 Cough & Cold 27,137 4,584 — 31,721 Women's Health 60,946 3,306 — 64,252 Gastrointestinal 30,737 10,321 — 41,058 Eye & Ear Care 23,352 3,164 — 26,516 Dermatologicals 21,508 470 — 21,978 Oral Care 22,177 2,656 — 24,833 Other OTC 1,594 1 — 1,595 Household Cleaning — — — — Total segment revenues $ 216,776 $ 24,638 $ — $ 241,414 Nine Months Ended December 31, 2018 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 86,221 $ 418 $ — $ 86,639 Cough & Cold 63,843 15,489 — 79,332 Women's Health 186,037 8,833 — 194,870 Gastrointestinal 94,065 24,261 — 118,326 Eye & Ear Care 73,669 8,778 — 82,447 Dermatologicals 71,968 1,607 — 73,575 Oral Care 67,516 8,050 — 75,566 Other OTC 4,182 3 — 4,185 Household Cleaning — — 19,811 19,811 Total segment revenues $ 647,501 $ 67,439 $ 19,811 $ 734,751
Information about our Segment Revenues by Geographic Area	Our total segment revenues by geographic area are as follows: Three Months Ended December 31, Nine Months Ended December 31, 2019 2018 2019 2018 United States $ 203,920 204,943 $ 604,263 $ 632,183 Rest of world 37,632 36,471 107,512 102,568 Total $ 241,552 $ 241,414 $ 711,775 $ 734,751
Information about our Consolidated Goodwill and Intangible Assets Allocated to Reportable Segments	Our consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: December 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 546,643 $ 30,992 $ 577,635 Intangible assets Indefinite-lived 2,195,616 76,650 2,272,266 Finite-lived, net 214,390 4,883 219,273 Intangible assets, net 2,410,006 81,533 2,491,539 Total $ 2,956,649 $ 112,525 $ 3,069,174 March 31, 2019 North American OTC International OTC Consolidated (In thousands) Goodwill $ 547,393 $ 31,190 $ 578,583 Intangible assets Indefinite-lived 2,195,617 77,574 2,273,191 Finite-lived, net 228,743 5,276 234,019 Intangible assets, net 2,424,360 82,850 2,507,210 Total $ 2,971,753 $ 114,040 $ 3,085,793

Business and Basis of Present_4

Business and Basis of Presentation (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2019	Apr. 01, 2019	Mar. 31, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Noncash financing activities	$ 800
Operating lease right-of-use assets	31,342	$ 17,435	$ 0
Operating lease liabilities, current portion	(6,377)	(5,697)	0
Long-term operating lease liabilities, net of current portion	$ (26,200)	(13,296)	0
Other accrued liabilities		(59,105)	$ (60,663)
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets		17,435
Operating lease liabilities, current portion		(5,697)
Long-term operating lease liabilities, net of current portion		(13,296)
Other accrued liabilities		$ 1,558

Divestitures (Details)

Divestitures (Details) - Household Cleaning - Divestiture $ in Millions	Jul. 02, 2018USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from disposal	$ 65.9
Pre-tax gain on divestiture	$ 1.3

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 10,356	$ 17,082
Work in process	309	161
Finished goods	110,698	102,637
Inventories	121,363	119,880
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 8,000	$ 5,500

Goodwill (Details)

Goodwill (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2019USD ($)
Goodwill [Line Items]
Goodwill	$ 742,294
Accumulated impairment loss	(163,711)
Goodwill, net	578,583
Goodwill, transfers	(750)
Effects of foreign currency exchange rates	(198)
Goodwill	741,346
Accumulated impairment loss	(163,711)
Goodwill, net	577,635
North American OTC Healthcare
Goodwill [Line Items]
Goodwill	711,104
Accumulated impairment loss	(163,711)
Goodwill, net	547,393
Goodwill, transfers	(750)
Effects of foreign currency exchange rates	0
Goodwill	710,354
Accumulated impairment loss	(163,711)
Goodwill, net	546,643
International OTC Healthcare
Goodwill [Line Items]
Goodwill	31,190
Accumulated impairment loss	0
Goodwill, net	31,190
Goodwill, transfers	0
Effects of foreign currency exchange rates	(198)
Goodwill	30,992
Accumulated impairment loss	0
Goodwill, net	$ 30,992

Intangible Assets, net (Activit

Intangible Assets, net (Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			$ 2,273,191
Indefinite-lived trademarks, ending balance	$ 2,272,266		2,272,266
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance			2,663,474
Totals, gross, effects of foreign currency exchange rate			950
Totals, gross, ending balance	2,662,524		2,662,524
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			156,264
Accumulated amortization, additions	4,900	$ 5,300	14,725	$ 16,500
Accumulated amortization, effects of foreign exchange rates			(4)
Accumulated amortization, ending balance	170,985		170,985
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	219,273		219,273		$ 234,019
Intangible Assets, Net [Abstract]
Intangible assets, net	2,491,539		2,491,539		$ 2,507,210
Finite-Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite-lived trademarks and customer relationships, beginning balance			390,283
Finite-lived trademarks and customer relationships, effects of foreign currency exchange rate			25
Finite-lived trademarks and customer relationships, ending balance	390,258		390,258
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Accumulated amortization, beginning balance			156,264
Accumulated amortization, additions			14,725
Accumulated amortization, effects of foreign exchange rates			(4)
Accumulated amortization, ending balance	170,985		170,985
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived, net	219,273		219,273
Indefinite- Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite-lived trademarks, beginning balance			2,273,191
Indefinite lived trademarks, effects of foreign currency exchange rate			(925)
Indefinite-lived trademarks, ending balance	$ 2,272,266		$ 2,272,266

Intangible Assets, net (Narrati

Intangible Assets, net (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 4,900	$ 5,300	$ 14,725	$ 16,500
Remainder of the year	4,900		4,900
2021	19,600		19,600
2022	19,600		19,600
2023	19,600		19,600
2024	19,600		19,600
Thereafter	$ 136,000		$ 136,000

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	May 31, 2019	May 13, 2019	Apr. 01, 2019	Mar. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 31,342			$ 17,435	$ 0
Operating lease liability	32,577
Finance lease, right-of-use asset	5,895
Finance lease liability	5,884
GEODIS
Lessee, Lease, Description [Line Items]
Term of contract		5 years
Renewal term		5 years
Operating lease right-of-use assets			$ 18,900
Operating lease liability			$ 18,900
Finance lease, right-of-use asset	6,100
Finance lease liability	$ 6,100
Minimum
Lessee, Lease, Description [Line Items]
Term of contract	1 year
Renewal term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Term of contract	10 years
Renewal term	6 years

Leases (Lease Cost) (Details)

Leases (Lease Cost) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2019
Leases [Abstract]
Amortization of right-of-use assets	$ 207	$ 207
Interest on lease liabilities	34	34
Operating lease cost	2,239	5,697
Short term lease cost	28	78
Variable lease cost	15,731	48,396
Sublease income	(833)	(2,607)
Total net lease cost	$ 17,406	$ 51,805

Leases (Lease Maturities) (Deta

Leases (Lease Maturities) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Operating Leases
2020 (Remaining three months ending March 31, 2020)	$ 2,400
2021	7,073
2022	6,551
2023	6,307
2024	6,294
Thereafter	9,095
Total undiscounted lease payments	37,720
Less amount of lease payments representing interest	(5,143)
Total present value of lease payments	32,577
Financing Lease
2020 (Remaining three months ending March 31, 2020)	336
2021	1,342
2022	1,342
2023	1,342
2024	1,342
Thereafter	672
Total undiscounted lease payments	6,376
Less amount of lease payments representing interest	(492)
Total present value of lease payments	5,884
Total
2020 (Remaining three months ending March 31, 2020)	2,736
2021	8,415
2022	7,893
2023	7,649
2024	7,636
Thereafter	9,767
Total undiscounted lease payments	44,096
Less: amount of lease payments representing interest	(5,635)
Total present value of lease payments	$ 38,461

Leases (Additional Information)

Leases (Additional Information) (Details)	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term - operating leases	5 years 5 months 26 days
Weighted average remaining lease term - finance leases	4 years 9 months
Weighted average discount rate - operating leases	5.27%
Weighted average discount rate - finance leases	3.49%

Leases (Lease Maturities Under

Leases (Lease Maturities Under Prior Guidance) (Details) $ in Thousands	Mar. 31, 2019USD ($)
Operating Leased Assets [Line Items]
2020	$ 3,142
2021	2,881
2022	2,478
2023	1,789
2024	1,705
Thereafter	6,780
Total	18,775
Facilities
Operating Leased Assets [Line Items]
2020	2,828
2021	2,633
2022	2,265
2023	1,684
2024	1,705
Thereafter	6,780
Total	17,895
Equipment
Operating Leased Assets [Line Items]
2020	314
2021	248
2022	213
2023	105
2024	0
Thereafter	0
Total	$ 880

Other Accrued Liabilities (Deta

Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Payables and Accruals [Abstract]
Accrued marketing costs	$ 36,774	$ 31,228
Accrued compensation costs	8,906	10,958
Accrued broker commissions	1,462	1,361
Income taxes payable	6,216	88
Accrued professional fees	4,145	2,441
Accrued production costs	8,092	6,788
Other accrued liabilities	11,015	7,799
Total other accrued liabilities	$ 76,610	$ 60,663

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details) - USD ($)	Dec. 11, 2019	Dec. 02, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Debt Instrument [Line Items]
Line of credit facility, amount outstanding			$ 1,701,313,000		$ 1,701,313,000		$ 1,798,598,000
Loss on extinguishment of debt			$ 2,155,000	$ 0	$ 2,155,000	$ 0
2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400,000,000
Debt instrument, stated interest rate		5.125%
2019 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			5.125%		5.125%
2012 ABL Revolver
Debt Instrument [Line Items]
Debt instrument, amended term	5 years
Commitment fee percentage	0.25%
2012 ABL Revolver | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
2012 ABL Revolver | LIBOR | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, if increased	1.25%
2012 ABL Revolver | LIBOR | Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, if increased	1.50%
2012 ABL Revolver | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.00%
2012 ABL Revolver | Base Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, if increased	0.25%
2012 ABL Revolver | Base Rate | Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate, if increased	0.50%
2016 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			6.375%		6.375%
2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			5.375%		5.375%
Early repayment of senior debt		$ 400,000,000
Loss on extinguishment of debt					$ 2,200,000
2013 Senior Notes | Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			5.375%		5.375%
Revolving Credit Facility | 2012 ABL Revolver
Debt Instrument [Line Items]
Line of credit facility, amount outstanding			$ 0		$ 0
Borrowing capacity			$ 153,300,000		$ 153,300,000

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($)	Dec. 11, 2019	Dec. 31, 2019	Dec. 02, 2019	Mar. 31, 2019
Debt Instrument [Line Items]
Total long-term debt (including current portion)		$ 1,717,000,000		$ 1,813,000,000
Less: unamortized debt costs		(15,687,000)		(14,402,000)
Long-term debt, net		$ 1,701,313,000		1,798,598,000
2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		5.375%
2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate			5.125%
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Total long-term debt (including current portion)		$ 0		75,000,000
Long-term debt, net		$ 0
2012 ABL Revolver | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.00%
2012 ABL Revolver | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		6.375%
Total long-term debt (including current portion)		$ 600,000,000		600,000,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		5.375%
Total long-term debt (including current portion)		$ 0		400,000,000
Senior Notes | 2019 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate		5.125%
Total long-term debt (including current portion)		$ 400,000,000		0
Term B-5 Loans | 2012 Senior Notes
Debt Instrument [Line Items]
Total long-term debt (including current portion)		$ 717,000,000		$ 738,000,000
Term B-5 Loans | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		2.00%
Debt instrument, variable rate, minimum		0.00%
Term B-5 Loans | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Debt instrument, variable rate, minimum		1.00%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Aggregate Future Principal Payments
2020 (remaining three months ending March 31, 2020)	$ 0
2021	0
2022	0
2023	0
2024	1,317,000
Thereafter	400,000
Total long-term debt (including current portion)	$ 1,717,000	$ 1,813,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Senior Notes | 2016 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 600,000	$ 600,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	0	400,000
Senior Notes | 2019 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	0
Term Loans | 2012 Term B-5 Loans | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	717,000	738,000
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	0	75,000
Fair Value, Measurements, Recurring | Senior Notes | 2016 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	623,250	606,000
Fair Value, Measurements, Recurring | Senior Notes | 2013 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	0	401,500
Fair Value, Measurements, Recurring | Senior Notes | 2019 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	418,000	0
Fair Value, Measurements, Recurring | Term Loans | 2012 Term B-5 Loans | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	720,585	728,775
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 0	$ 75,000

Stockholders' Equity (Details)

Stockholders' Equity (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2019USD ($)vote$ / sharesshares	Dec. 31, 2018shares	Dec. 31, 2019USD ($)vote$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Mar. 31, 2019$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Dividends declared on common stock | $			$ 0
Stock repurchased during period (in shares) | shares			1,622,544	1,449,750
Stock acquired, average cost per share (in USD per share) | $ / shares			$ 30.80	$ 34.47
Treasury stock acquired | $	$ 94,000		$ 50,950,000	$ 52,259,000
Restricted Shares
Class of Stock [Line Items]
Stock repurchased during period (in shares) | shares	2,481	0	31,018	68,939
Stock acquired, average cost per share (in USD per share) | $ / shares	$ 37.95		$ 31.39	$ 33.09
Treasury stock acquired | $			$ 50,000,000	$ 50,000,000

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ 1,156,494,000	$ 1,095,831,000	$ 1,112,790,000	$ 1,233,120,000	$ 1,193,238,000	$ 1,178,610,000
Reclassification from accumulated other comprehensive loss into earnings	0	0
Cumulative translation adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	(27,189,000)	(26,878,000)
Unrecognized net gain on pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	1,131,000	1,131,000
Accumulated other comprehensive income, accumulated tax	300,000	300,000
Accumulated other comprehensive loss, net of tax
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shareholders' equity	$ (26,058,000)	$ (25,747,000)	$ (29,555,000)	$ (26,454,000)	$ (24,434,000)	$ (19,315,000)

Earnings Per Share (Computation

Earnings Per Share (Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Numerator
Net income	$ 38,058	$ 38,167	$ 105,235	$ 103,474
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	50,378	51,881	50,840	52,119
Dilutive effect of nonvested restricted stock units and options issued to employees and directors (in shares)	453	321	386	312
Denominator for diluted earnings per share (in shares)	50,831	52,202	51,226	52,431
Earnings per Common Share:
Basic earnings per share (in USD per share)	$ 0.76	$ 0.74	$ 2.07	$ 1.99
Diluted earnings per share (in USD per share)	$ 0.75	$ 0.73	$ 2.05	$ 1.97

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0.6	0.4	0.9	0.5

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Thousands	Jul. 30, 2019shares	May 13, 2019$ / sharesshares	May 06, 2019$ / sharesshares	May 31, 2014shares	Jun. 30, 2014shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Share-based Compensation, Aggregate Disclosures:
Maximum number of shares per participant, 12 month period (in shares)				1,000,000	2,500,000
Extension of plan term					10 years
Share-based compensation costs charged against income | $						$ 1,800	$ 1,900	$ 5,700	$ 6,200
Tax benefit recognized from share-based compensation expense | $						300	$ 300	900	1,100
Unrecognized compensation costs related to nonvested awards | $						$ 7,500		$ 7,500
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition								1 year
Total fair value of vested shares | $								$ 7,800	12,000
Proceeds from exercise of stock options | $								1,007	2,931
Tax benefit realized from exercise of stock options | $								$ 600	$ 1,300
Shares available for issuance under the Plan (in shares)						1,500,000		1,500,000
Stock options granted (in shares)								302,700	294,500
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share) | $ / shares								$ 10.83	$ 10.22
Options exercised, aggregate intrinsic value | $								$ 300
Performance Shares
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)			98,644
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Share grants in period (in shares)	4,183	7,287	89,286					220,300	226,400
Restricted Stock Units (RSUs) | Employee
Restricted Shares
Award vesting period								3 years
Restricted Stock Units (RSUs) | Employee | Minimum
Restricted Shares
Award vesting period								3 years
Restricted Stock Units (RSUs) | Director
Restricted Shares
Conversion ratio for common shares into which each RSU may be converted								1
Period following director's term in which RSUs may be settled								6 months
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)		21,194	281,487
Stock options granted, exercise price (in USD per share) | $ / shares		$ 30.19	$ 30.56
Stock Options | Minimum
Restricted Shares
Award vesting period								3 years
Stock Options | Maximum
Restricted Shares
Award vesting period								5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant								10 years
Long-term Equity Incentive Plan, 2005
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)				5,000,000
Number of additional shares authorized (in shares)					1,800,000

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	Jul. 30, 2019	May 13, 2019	May 06, 2019	Dec. 31, 2019	Dec. 31, 2018
Shares
Outstanding, beginning of period (in shares)				413,000	393,500
Granted (in shares)	4,183	7,287	89,286	220,300	226,400
Vested and issued (in shares)				(73,000)	(175,800)
Forfeited (in shares)				(34,200)	(31,100)
Outstanding, end of period (in shares)				526,100	413,000
Vested, end of period (in shares)				138,300	113,200
Weighted Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)				$ 36.58	$ 44.13
Granted, weighted-average grant-date fair value (in USD per share)				31.02	30.09
Vested and issued, weighted-average grant-date fair value (in USD per share)				47.68	43.05
Forfeited, weighted-average grant-date fair value (in USD per share)				35.97	48.32
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)				32.74	36.58
Vested, end of period, weighted-average grant-date fair value (in USD per share)				$ 31.71	$ 31.05

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		29.60%
Expected dividends	$ 0	$ 0
Expected term in years		6 years
Risk-free rate		2.90%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	30.90%
Expected term in years	6 years
Risk-free rate	2.30%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	31.30%
Expected term in years	7 years
Risk-free rate	2.40%

Share-Based Compensation (Sto_2

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Shares
Outstanding, beginning of period (in shares)	944,600	873,200
Granted (in shares)	302,700	294,500
Exercised (in shares)	(36,000)	(97,700)
Forfeited or expired (in shares)	(155,300)	(125,400)
Outstanding, end of period (in shares)	1,056,000	944,600
Exercisable, end of period (in shares)	602,000	499,400
Weighted Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 38.45	$ 41.79
Granted, weighted-average exercise price (in USD per share)	30.53	29.46
Exercised, weighted-average exercise price (in USD per share)	27.96	30.02
Forfeited or expired, weighted-average exercise price (in USD per share)	41.18	47.16
Outstanding, end of period, weighted-average exercise price (in USD per share)	36.14	38.45
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 38.90	$ 37.87
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	6 years 10 months 24 days	7 years 2 months 12 days
Exercisable, end of period, weighted-average remaining contractual term	5 years 4 months 24 days	5 years 9 months 18 days
Outstanding, end of period, aggregate intrinsic value	$ 9,035	$ 2,477
Exercisable, end of period, aggregate intrinsic value	$ 4,756	$ 2,076

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Effective income tax rate (percent)	24.70%	25.20%	25.20%	26.60%
Income taxes paid			$ 21,212	$ 24,404
Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Income taxes paid				$ 19,100

Employee Retirement Plans (Expe

Employee Retirement Plans (Expected Return on Plan Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Interest cost	$ 575	$ 599	$ 1,729	$ 1,819
Expected return on assets	(722)	(767)	(2,164)	(2,303)
Net periodic benefit income	$ (147)	$ (168)	$ (435)	$ (484)

Employee Retirement Plans (Narr

Employee Retirement Plans (Narrative) (Details)	9 Months Ended
	Dec. 31, 2019USD ($)
Non-qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	$ 300,000
Expected employer contributions, remainder of fiscal year	100,000
Qualified Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Employer contributions	1,000,000
Expected employer contributions, remainder of fiscal year	$ 0

Concentrations of Risk (Details

Concentrations of Risk (Details) - manufacturer	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Concentration Risk [Line Items]
Number of third-party manufacturers	113	112	113	112
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	23.20%	22.30%	23.40%	23.50%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			66.20%	60.40%
Number of third-party manufacturers with long-term contracts			17	33
Top 5 brands | Sales | Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	41.70%	41.70%	42.80%	42.80%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Segment Reporting Information, Profit (Loss):
Total revenues	$ 241,552	$ 241,414	$ 711,775	$ 734,751
Cost of sales	104,057	102,179	303,462	317,421
Gross profit	137,495	139,235	408,313	417,330
Advertising and promotion	33,559	34,504	107,027	108,657
Contribution margin	103,936	104,731	301,286	308,673
Other operating expenses	27,532	27,190	84,048	87,721
Operating income	76,404	77,541	217,238	220,952
Other expense	25,850	26,545	76,622	79,977
Income before income taxes	50,554	50,996	140,616	140,975
Provision for income taxes	12,496	12,829	35,381	37,501
Net income	38,058	38,167	105,235	103,474
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	214,892	216,776	639,554	647,501
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	26,660	24,638	72,221	67,439
Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	0	0	19,811
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	214,892	216,776	639,554	647,501
Cost of sales	93,937	91,594	275,679	272,754
Gross profit	120,955	125,182	363,875	374,747
Advertising and promotion	29,025	30,316	94,634	96,899
Contribution margin	91,930	94,866	269,241	277,848
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	26,660	24,638	72,221	67,439
Cost of sales	10,120	10,585	27,783	28,079
Gross profit	16,540	14,053	44,438	39,360
Advertising and promotion	4,534	4,188	12,393	11,328
Contribution margin	12,006	9,865	32,045	28,032
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Total revenues	0	0	0	19,811
Cost of sales	0	0	0	16,588
Gross profit	0	0	0	3,223
Advertising and promotion	0	0	0	430
Contribution margin	0	0	0	2,793
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Total revenues	$ 600	$ 1,300	$ 2,100	$ 5,600

Business Segments (Revenue) (De

Business Segments (Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 241,552	$ 241,414	$ 711,775	$ 734,751
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,505	29,461	86,344	86,639
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	29,963	31,721	79,005	79,332
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	62,119	64,252	186,699	194,870
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	44,742	41,058	124,541	118,326
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	27,254	26,516	82,489	82,447
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,884	21,978	78,927	73,575
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,795	24,833	69,928	75,566
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,290	1,595	3,842	4,185
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	19,811
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	214,892	216,776	639,554	647,501
North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	28,330	29,325	85,696	86,221
North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	25,221	27,137	63,067	63,843
North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	58,576	60,946	177,832	186,037
North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	32,645	30,737	96,431	94,065
North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	24,095	23,352	73,134	73,669
North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	23,286	21,508	77,063	71,968
North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	21,451	22,177	62,493	67,516
North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	1,288	1,594	3,838	4,182
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	26,660	24,638	72,221	67,439
International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	175	136	648	418
International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	4,742	4,584	15,938	15,489
International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,543	3,306	8,867	8,833
International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	12,097	10,321	28,110	24,261
International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	3,159	3,164	9,355	8,778
International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	598	470	1,864	1,607
International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2,344	2,656	7,435	8,050
International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	2	1	4	3
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	19,811
Household Cleaning | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	0	0	0	0
Household Cleaning | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total revenues	$ 0	$ 0	$ 0	$ 19,811

Business Segments (Revenue by G

Business Segments (Revenue by Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 241,552	$ 241,414	$ 711,775	$ 734,751
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	203,920	204,943	604,263	632,183
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenues	$ 37,632	$ 36,471	$ 107,512	$ 102,568

Business Segments (Goodwill and

Business Segments (Goodwill and Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Mar. 31, 2019
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 577,635	$ 578,583
Intangible assets
Indefinite-lived	2,272,266	2,273,191
Finite-lived, net	219,273	234,019
Intangible assets, net	2,491,539	2,507,210
Total	3,069,174	3,085,793
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	546,643	547,393
Intangible assets
Indefinite-lived	2,195,616	2,195,617
Finite-lived, net	214,390	228,743
Intangible assets, net	2,410,006	2,424,360
Total	2,956,649	2,971,753
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	30,992	31,190
Intangible assets
Indefinite-lived	76,650	77,574
Finite-lived, net	4,883	5,276
Intangible assets, net	81,533	82,850
Total	$ 112,525	$ 114,040

Uncategorized Items - pbh-20191

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 1,343,000